

Date: 14.08.2023

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Sub: - Unaudited Financial Result of the Company under Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 for the Quarter ended on 30th June, 2023

Company Scrip Code: 532167

Dear Sir(s),

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, please find enclosed herewith:

1. Unaudited Financial Results of the Company, for the Quarter ended on 30th June, 2023, alongwith Limited Review Report of the company.

The aforesaid result has been approved by the Board of Directors at their meeting held on 14th August, 2023.

This is for your information and record.

Thanking You,

Yours faithfully,
For **Omkar Pharmachem Limited**



Bhawani Shankar Goyal
(Managing Director)
DIN: 03255804

Address: House No. - 155/2, First Floor, Gali No - 2
Near Gurudwara, Govindpuri, Kalkaji- 110019
Delhi
Encl: a/a



Limited Review Report to the Board of Directors of **Omkar Pharmachem Limited**
for quarter ended on 30th June, 2023

We have reviewed the accompanying statement of unaudited financial results of **Omkar Pharmachem Limited** for the quarter ended on 30th June, 2023.

This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and; thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure

For Rajesh J. Shah & Associates
Chartered Accountants
FRN 108407W

CA RAJESH J. SHAH
Partner
M. NO. 040268



Place: Ahmedabad
Date : 14/08/2023

ॐ Omkar Pharmachem Ltd.

Statement of Standalone Unaudited Financial Results for the Quarter Ended on 30th June 2023

(Rs. in lakh except per share data)					
Sr. No.	Particulars	Quarter Ended on			Fiancial Year ended on
		30-06-2023	31-03-2023	30-06-2022	31-03-2023
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Part-I				
1	Income from operations				
	a)Net Sales/ Income from Operations	0.00	0.00	0.00	0.00
	b)Other Operating Income	13.50	13.50	13.50	54.00
		13.50	13.50	13.50	54.00
2	Other Income	0.00	0.30	0.00	0.30
3	Net Total income	13.50	13.80	13.50	54.30
4	Expenses				
	a) Cost of material consumed	0.00	0.00	0.00	0.00
	b) Purchase of Stock-in-trade	0.00	0.00	0.00	0.00
	c) Changes in Inventories of Finished Goods, WIP and Stock-in trade	0.00	0.00	0.00	0.00
	d) Employee benefits expenses	2.94	1.81	4.36	13.87
	e) Finance Cost	0.00	4.63	0.00	4.63
	f) Depreciation and Amortization Expenses	0.06	0.07	0.07	0.27
	g) Other Expenses	5.67	1.46	4.50	9.08
	Total Expenses	8.67	7.97	8.93	27.85
5	Profit(Loss) before exceptional items and tax(3-4)	4.83	5.83	4.57	26.45
6	Exceptional items	0.00	0.00	0.00	0.00
7	Profit(Loss) from before Tax(5±6)	4.83	5.83	4.57	26.45
8	Tax Expense	0.00	6.67	0.00	6.67
9	Profit(Loss) for the period (7-8)	4.83	(0.84)	4.57	19.78
10	Other Comprehensive Income (Expense)	0.00	0.00	0.00	0.00
11	Total Comprehensive Income for the period (9±10)	4.83	(0.84)	4.57	19.78
12	Paid up Equity Share Capital (Face Value Rs. 10/-each)	1008.37	1008.37	1008.37	1008.37
13	Other equity		(104.00)		(104.00)
	Earning Per Share(before & after extraordinary items)(of				
14	Rs. 10 each)(not annualised) Basic and diluted Rs.	0.0479	(0.0083)	0.0453	0.1962

Notes

- The above results have been reviewed by the audit committee & approved by the Board of Directors at their respective meeting held on 14th August 2023.
- Corresponding previous period figures are regrouped/rearranged wherever necessary, to make them comparable.
- The financial result for the Quarter ended on 30-06-2023 has been prepared in accordance with the IND-AS specified under section 133 of the companies Act and rules made thereunder.
- The IND-AS regarding segment reporting is not applicable to the company.

By order of the Board

(Bhawani Shankar Goyal)

Managing Director

DIN No. 03255804

House No.155/2, First Floor, Gali No - 2, Near
Gurudwara, Govindpuri, Kalkaji, Delhi-110019

Place: Ahmedabad

Date : 14-08-2023